Christine Brezden-Masley


Associate Scientist, Li Ka Shing Knowledge Institute


Dr. Christine Brezden-Masley is a practicing Medical Oncologist and the Division Head of Hematology / Oncology at St. Michael’s Hospital in Toronto and is the Head of the Oncology Clinical Research Group there.  She obtained her PhD in Medical Biophysics at Princess Margaret Hospital in Toronto and her Medical Degree from the University of Toronto. She is currently an Associate Professor at the University of Toronto. She is the founder of the COMET (Community Oncologists of Metropolitan Toronto) Clinical Trials Consortium, a web-based virtual network promoting cancer clinical trials throughout the Toronto Region.  She treats both Breast and GI (colorectal and gastric cancers) malignancies and these are the major areas of her clinical research.  Her main area of clinical research is cardiotoxicity from cancer therapy and is the Co-Chair of the annual Canadian Cardio-Oncology Network meeting, a collaborative national meeting improving cardiac heath in cancer patients. She is active in research, education and has been instrumental in the clinical development of the cancer program at St. Michael’s Hospital.

Please note: Dr. Brezden-Masley is no longer accepting summer students for 2018.

Recent Publications

  1. Lohmann, AE, Dowling, RJO, Ennis, M, Amir, E, Elser, C, Brezden-Masley, C et al.. Association of Metabolic, Inflammatory, and Tumor Markers With Circulating Tumor Cells in Metastatic Breast Cancer. JNCI Cancer Spectr. 2018;2 (2):pky028. doi: 10.1093/jncics/pky028. PubMed PMID:30035251 PubMed Central PMC6044231.
  2. Matutino, A, Joy, AA, Brezden-Masley, C, Chia, S, Verma, S. Hormone receptor-positive, HER2-negative metastatic breast cancer: redrawing the lines. Curr Oncol. 2018;25 (Suppl 1):S131-S141. doi: 10.3747/co.25.4000. PubMed PMID:29910656 PubMed Central PMC6001771.
  3. AlFakeeh, A, Brezden-Masley, C. Overcoming endocrine resistance in hormone receptor-positive breast cancer. Curr Oncol. 2018;25 (Suppl 1):S18-S27. doi: 10.3747/co.25.3752. PubMed PMID:29910644 PubMed Central PMC6001756.
  4. Lui, A, Mulder, K, Brezden-Masley, C, Vickers, M, Monzon, J, Kennecke, H et al.. A multicentre, open-label phase II study of Irinotecan, capecitabine (Xeloda®), and Oxaliplatin (IXO) as first-line treatment in patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma. Invest New Drugs. 2018;36 (4):674-682. doi: 10.1007/s10637-018-0599-4. PubMed PMID:29725881 .
  5. Naseem, M, Barzi, A, Brezden-Masley, C, Puccini, A, Berger, MD, Tokunaga, R et al.. Outlooks on Epstein-Barr virus associated gastric cancer. Cancer Treat. Rev. 2018;66 :15-22. doi: 10.1016/j.ctrv.2018.03.006. PubMed PMID:29631196 PubMed Central PMC5964025.
  6. Ong, G, Brezden-Masley, C, Dhir, V, Deva, DP, Chan, KKW, Chow, CM et al.. Myocardial strain imaging by cardiac magnetic resonance for detection of subclinical myocardial dysfunction in breast cancer patients receiving trastuzumab and chemotherapy. Int. J. Cardiol. 2018;261 :228-233. doi: 10.1016/j.ijcard.2018.03.041. PubMed PMID:29555336 .
  7. Chiu, JW, Krzyzanowska, MK, Serra, S, Knox, JJ, Dhani, NC, Mackay, H et al.. Molecular Profiling of Patients With Advanced Colorectal Cancer: Princess Margaret Cancer Centre Experience. Clin Colorectal Cancer. 2018;17 (1):73-79. doi: 10.1016/j.clcc.2017.10.010. PubMed PMID:29128266 .
  8. Wilson, FR, Coombes, ME, Wylie, Q, Yurchenko, M, Brezden-Masley, C, Hutton, B et al.. Herceptin® (trastuzumab) in HER2-positive early breast cancer: protocol for a systematic review and cumulative network meta-analysis. Syst Rev. 2017;6 (1):196. doi: 10.1186/s13643-017-0588-2. PubMed PMID:29017563 PubMed Central PMC5634826.
  9. Tang, GH, Acuna, SA, Sevick, L, Yan, AT, Brezden-Masley, C. Incidence and identification of risk factors for trastuzumab-induced cardiotoxicity in breast cancer patients: an audit of a single "real-world" setting. Med. Oncol. 2017;34 (9):154. doi: 10.1007/s12032-017-1018-y. PubMed PMID:28779423 .
  10. Barthur, A, Brezden-Masley, C, Connelly, KA, Dhir, V, Chan, KK, Haq, R et al.. Longitudinal assessment of right ventricular structure and function by cardiovascular magnetic resonance in breast cancer patients treated with trastuzumab: a prospective observational study. J Cardiovasc Magn Reson. 2017;19 (1):44. doi: 10.1186/s12968-017-0356-4. PubMed PMID:28395671 PubMed Central PMC5387372.
Search PubMed

Affiliations & Other Activities

  • Head, Oncology Clinical Research Group, St. Michael’s Hospital
  • Head, Division of Hematology/Oncology, St. Michael’s Hospital
  • Oncologist, Division of Hematology/Oncology, St. Michael’s Hospital
  • Associate Professor, Department of Medicine, University of Toronto
  • Co-chair, Canadian Cardiac Oncology Network (CCON)
  • Founder, COMET Clinical Trials Consortium